scholarly journals Epidermal Growth Factor Receptor Protein: A Biological Marker for Oral Precancer and Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Ashish Mahendra ◽  
Balasundari Shreedhar ◽  
Mala Kamboj ◽  
Arun Singh ◽  
Abhishek Singh ◽  
...  
Keyword(s):  
Indian Subcontinent ◽  
Protein A ◽  
Growth Factor Receptor ◽  
Biological Marker ◽  
Oral Leukoplakia ◽  
Receptor Protein ◽  
Cancer Therapies ◽  
Egfr Expression ◽  
Promising Target ◽  
Epidermal Growth

Background. The aim of the present paper was to study the expression and overexpression of EGFR in oral leukoplakia and cancer and at the same time assess the expression of EGFR in various histological grades of oral leukoplakia and OSCC in the Indian subcontinent. Methods. The study was conducted with routine H&E and IHC staining on 40 archival tissues. Results. Positive EGFR staining was present in all the cases 100% (30/30) out of which 7 (46.7%) cases of OSCC showed >75% EGFR expression and 8 (53.3%) cases of oral leukoplakia showed 25% EGFR expression. A statistically significant correlation was found in OSCC, OL and controls. Conclusions. EGFR may represent a promising target for novel molecular cancer therapies. EGFR expression levels in the premalignant lesion appear to be a sensitive factor in predicting the neoplastic potential of dysplastic tissues. This suggests that EGFR may serve as a biological marker to identify high-risk subgroups and guide prophylactic therapy.

scholarly journals Bi-Functional Radiotheranostics of 188Re-Liposome-Fcy-hEGF for Radio- and Chemo-Therapy of EGFR-Overexpressing Cancer Cells

2021 ◽  
Vol 22 (4) ◽  
pp. 1902 ◽  
Author(s):  
Yi-Shu Huang ◽  
Wei-Chuan Hsu ◽  
Chien-Hong Lin ◽  
Sheng-Nan Lo ◽  
Chu-Nian Cheng ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Cancer Cells ◽  
Tumor Cells ◽  
Cytotoxic Effect ◽  
Cytosine Deaminase ◽  
Growth Factor Receptor ◽  
Size Exclusion ◽  
Specific Therapy ◽  
Egfr Expression ◽  
Epidermal Growth

Epidermal growth factor receptor (EGFR) specific therapeutics is of great importance in cancer treatment. Fcy-hEGF fusion protein, composed of yeast cytosine deaminase (Fcy) and human EGF (hEGF), is capable of binding to EGFR and enzymatically convert 5-fluorocytosine (5-FC) to 1000-fold toxic 5-fluorocuracil (5-FU), thereby inhibiting the growth of EGFR-expressing tumor cells. To develop EGFR-specific therapy, 188Re-liposome-Fcy-hEGF was constructed by insertion of Fcy-hEGF fusion protein onto the surface of liposomes encapsulating of 188Re. Western blotting, MALDI-TOF, column size exclusion and flow cytometry were used to confirm the conjugation and bio-activity of 188Re-liposome-Fcy-hEGF. Cell lines with EGFR expression were subjected to treat with 188Re-liposome-Fcy-hEGF/5-FC in the presence of 5-FC. The 188Re-liposome-Fcy-hEGF/5-FC revealed a better cytotoxic effect for cancer cells than the treatment of liposome-Fcy-hEGF/5-FC or 188Re-liposome-Fcy-hEGF alone. The therapeutics has radio- and chemo-toxicity simultaneously and specifically target to EGFR-expression tumor cells, thereby achieving synergistic anticancer activity.

scholarly journals Epidermal Growth Factor Receptor Expression in the Corneal Epithelium

Cells ◽  
2021 ◽  
Vol 10 (9) ◽  
pp. 2409
Author(s):  
Joanne L. Peterson ◽  
Brian P. Ceresa
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Corneal Epithelium ◽  
Growth Factor Receptor ◽  
Receptor Expression ◽  
Cancer Therapies ◽  
Anterior Portion ◽  
Increased Risk ◽  
Epidermal Growth

A properly functioning cornea is critical to clear vision and healthy eyes. As the most anterior portion of the eye, it plays an essential role in refracting light onto the retina and as an anatomical barrier to the environment. Proper vision requires that all layers be properly formed and fully intact. In this article, we discuss the role of the epidermal growth factor receptor (EGFR) in maintaining and restoring the outermost layer of the cornea, the epithelium. It has been known for some time that the addition of epidermal growth factor (EGF) promotes the restoration of the corneal epithelium and patients using EGFR inhibitors as anti-cancer therapies are at increased risk of corneal erosions. However, the use of EGF in the clinic has been limited by downregulation of the receptor. More recent advances in EGFR signaling and trafficking in corneal epithelial cells have provided new insights in how to overcome receptor desensitization. We examine new strategies for overcoming the limitations of high ligand and receptor expression that alter trafficking of the ligand:receptor complex to sustain receptor signaling.

scholarly journals Epidermal growth factor receptor protein expression in lung cancer and survival analysis

2018 ◽  
Vol 5 (3) ◽  
pp. 550
Author(s):  
Shivalingaswamy Salimath ◽  
Jayaraj B. S. ◽  
Mahesh P. A. ◽  
M. D. Majeed Pasha ◽  
Lokesh K. S. ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Multivariate Analysis ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Performance Status ◽  
Growth Factor Receptor ◽  
Egfr Expression ◽  
Epidermal Growth ◽  
Nsclc Patients

Background: Epidermal Growth Factor Receptor (EGFR) is one of the important molecules involved in lung cancer initiation and progression. Studies on over expression of EGFR and its survival in relation with Non-small cell lung cancer (NSCLC) patients have yielded controversial results. Prevalence of EGFR expression in NSCLC patients and 6-month survival in south Indian population is unknown.Methods: We carried out a prospective study in tertiary hospital. Diagnosed patients with NSCLC were included in the study and were interviewed with questionnaire containing demography and investigations like Chest X-ray, CT thorax, Bronchoscopy were recorded. EGFR expression analysis was done for all patients and were followed up monthly for 6 months and details of survival and treatment were collected. Cox regression analysis was used to assess their survival.Results: 50 patients with NSCLC were included. Forty-four (88%) were men, median age of study group was 65 years. Twenty-seven patients (54%) had Adenocarcinoma, 14 patients (28%) had Squamous cell carcinoma, 7 patients (14%) had poorly differentiated carcinoma and 2 patients (4%) had large cell carcinoma. Thirty-four (68%) samples were positive for EGFR expression. On multivariate analysis we found patients who took chemotherapy and with good performance status (Karnofsky score >65 and Eastern Cooperative Oncology Group >2.5) had better survival at 6 months.Conclusions: Patients with EGFR positivity had better survival with chemotherapy but worse with radiotherapy. Patients who took chemotherapy and had good performance status had better survival on multivariate analysis. We didn’t find any correlation between EGFR positivity and poor survival.

Sign in / Sign up

Export Citation Format

Share Document